TAXUS VI. In December 2002, we completed enrollment of our TAXUS VI clinical trial. TAXUS VI is an international trial studying 448 patients with complex coronary artery disease at 44 sites. It is designed to establish the safety and efficacy of the moderate-release formulation in the treatment of longer lesions. The trial – which includes the use of multiple stents – has a primary endpoint based on nine-month target vessel revascularization. This study is currently at 30-day follow-up.

WISDOM. The Company has initiated a transitional registry program (WISDOM) in a number of countries as part of a limited commercial launch. This international, multi-center, prospective, observational registry is collecting and analyzing real-world data. A registry program enlists large numbers of clinicians to document the performance of a specific therapy for a particular disease or condition. This registry has enrolled more than 300 patients.

Milestone II. The Company expects to begin a post-approval European registry shortly. The registry is targeting 100 sites and plans to enroll 2000 patients to study real-world usage patterns.

Back to Boston Scientific Drug-Eluting Stent Program